Three Recalls, Three Pharmacies, One Ingredient

In September, Centric Compounding recalled glutathione, Myers Cocktail, and Tri-Immune Boost injections after testing found elevated endotoxin levels. Nine adverse event reports had been filed. The FDA's language on endotoxins is unchanged and blunt: inflammatory reactions, anaphylactic shock, and death.

If that sounds familiar, it should. We covered an almost identical recall in August, from Victory Medical Center Pharmacy. A second pharmacy, Optimal Balance, recalled in August too. This is the third Texas pharmacy this year, and all three involved compounded glutathione.

Three pharmacies is not three accidents

The detail that turns this from a run of bad luck into a story is upstream of all three.

The two August facilities had sourced their glutathione from the same manufacturer, and the material was dietary supplement grade. The FDA used the occasion to remind compounders that supplement-grade ingredients are not appropriate for injectable drugs.

That sounds like paperwork. It is not.

Why the grade of an ingredient decides the outcome

Supplement-grade and injectable-grade material can be the same molecule at similar chemical purity. What differs is what the manufacturer is required to test for and control.

A supplement is swallowed. Your stomach acid and gut lining handle a level of bacterial debris that would never be acceptable in something injected, so supplement manufacturing is not built around endotoxin limits. Injectable-grade material is, because once something goes under the skin the body's outer defenses are bypassed entirely.

So a pharmacy can follow its own procedures carefully, work in a clean room, test the finished product for sterility, and still end up with a contaminated vial, because the problem arrived in the barrel of powder before anyone opened it. Buy that powder from a supplement supplier and you inherit its testing standards, whatever your own are.

That is also why one supplier can produce recalls at several pharmacies at once, which is exactly what appears to have happened here.

How this fits what we already knew

Three things this year now point the same direction.

• Inspections are thin. The study we covered on FDA oversight of outsourcing facilities found fewer than a quarter of newly registered facilities inspected over five years, and violations in every one that was.
• Purity certificates miss this entirely. Chromatography measures the molecule, not bacterial contamination. A vial can be 99 percent pure and still cause an endotoxin reaction.
• The ingredient supply chain is the weak link. That is the new piece. It is not enough to ask whether a pharmacy is licensed. What it buys, and to what standard, decides what ends up in the syringe.

The practical version for anyone using compounded injectables: the question worth asking a provider is not just who compounded this, but where the raw ingredient came from and whether it is pharmaceutical grade.

Three other things worth noting

Copper peptide injections. NPR reported on rising use of injected GHK-Cu, which has no published human safety data for that route. Specialists have raised concerns about copper accumulation and liver effects. Our page covers what the evidence does and does not show, and almost all of it is topical or laboratory work.

State boards are moving. Mississippi's nursing, pharmacy, and medical boards issued a joint warning to providers against using research-grade peptides, adding that having a patient sign a waiver does not relieve a clinician of their legal obligations. That is a notable line, because waivers are common in this corner of practice.

The counterfeit harms are getting specific. In Australia, a patient suffered a torn esophagus after injecting from a vial that contained semaglutide rather than the retatrutide on the label, most likely from severe vomiting at an unintended dose. Seven further cases of acute liver injury have been linked to counterfeit retatrutide. This is what the lab testing we wrote about, where only one of eighteen samples matched its label, looks like when it reaches actual people.

Source: Partnership for Safe Medicines, September 16, 2026.